Gene
GNAS
GNAS is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (42), Actionable biomarkers (1), Trial mentions (24), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention GNAS. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 2 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 22 of 11,460 | 0.19% |
| 2022 | 1 of 8,285 | 0.01% | 25 of 13,598 | 0.18% |
| 2021 | 2 of 8,692 | 0.02% | 22 of 15,045 | 0.15% |
| 2020 | 5 of 7,640 | 0.07% | 14 of 14,459 | 0.10% |
| 2019 | 0 of 7,300 | 0.00% | 24 of 12,159 | 0.20% |
| 2018 | 1 of 6,927 | 0.01% | 25 of 11,854 | 0.21% |
| 2017 | 1 of 6,558 | 0.02% | 15 of 11,595 | 0.13% |
Showing 10 of 37 years.
Assay-provider ledger (42)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | Clinical validationAnalytical validation | 3 | August 01, 2026 |
| Olympus Corporation of Americas | Reagent supplier | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 6 | August 01, 2026 |
| University of Pittsburgh Medical Center (UPMC) Molecular & Genomics Pathology (MGP) laboratory | Not a company | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| University of Pittsburgh Medical Center | Not a company | Clinical validation | 1 | April 01, 2026 |
Showing 5 of 42 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| GNAS (R201) | Jak Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (24)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00182533 | Trial eligibility (AACT) |
| NCT07341360 | Trial eligibility (AACT) |
| NCT05068024 | Trial eligibility (AACT) |
| NCT07122310 | Trial eligibility (AACT) |
| NCT05498961 | Trial eligibility (AACT) |
Showing 5 of 24 trial mentions.
Target-disease associations (604)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| ACTH-independent macronodular adrenal hyperplasia 1 | endocrine system disease | Variant curation (ClinVar / EVA) |
| ACTH-independent macronodular adrenal hyperplasia 1 | endocrine system disease | eva somatic |
| ACTH-independent macronodular adrenal hyperplasia 1 | endocrine system disease | genomics england |
Showing 5 of 604 associations.
Vendor sourcing (116)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple path... | View ClinVar record SCV002059109.1 |
| Aarhus University Hospital Skejby | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Entries referring to smokers attending more than one smoking cessation intervention (the latest entry will be used) * Smokers younger than 18 years of a... | View trial NCT04198688 |
| Aarhus University Hospital Skejby | Trial collaborator | Mentioned in trial textTrial free-text mention | GSP | View trial NCT04198688 |
| Allergan (Ireland) | Trial sponsor | Mentioned in trial textTrial free-text mention | GSP | View trial NCT02479139 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.691C>T (p.R231C) alteration is located in exon 9 (coding exon 9) of the GNAS gene. This alteration results from a C to T substitution at nucleotide pos... | View ClinVar record SCV003529957.2 |
Showing 5 of 116 sourcing records.
Trial-cited literature (269)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 10 |
| Genetic evaluation of pediatric pituitary adenomas and USP8-related genotype-phenotype correlations in Cushing's disease. | Pituitary | 2025 | 2 |
| Bone Turnover Markers: Basic Biology to Clinical Applications. | Endocrine reviews | 2023 | 261 |
| Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities. | Frontiers in endocrinology | 2023 | 80 |
| Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. | The Journal of clinical endocrinology and metabolism | 2023 | 71 |
Showing 5 of 269 papers.
Protein variant mentions (25)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.E130G | 1 | 2015 | PMID 28210698 |
| p.G289E | 1 | 2018 | PMID 29959430 |
| p.K100N | 1 | 2015 | PMID 25741868 |
| p.K91* | 1 | 2015 | PMID 25741868 |
| p.L46R | 1 | 2015 | PMID 25741868 |
Showing 5 of 25 variants.
Literature-extracted relations (102)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Thiazides | Chemical | associate |
Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response. | 2016 |
| Adenosine Monophosphate | Chemical | associate |
McCune Albright syndrome and bilateral adrenal hyperplasia: the GNAS mutation may only be present in adrenal tissue. | 2015 |
| CLONIDINE | Chemical | associate |
Pharmacogenetics of antihypertensive drug responses. | 2004 |
| Neoplasms | Disease | associate |
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations. | 2025 |
| Peritoneal Neoplasms | Disease | associate |
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations. | 2025 |
Showing 5 of 102 relation assertions.
Organizations publishing (308)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 23 | 1991 to 2025 |
| Mass General Brigham | Hospital | 11 | 2013 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 11 | 2014 to 2022 |
| Mayo Clinic | Hospital | 9 | 2014 to 2023 |
| The University of Texas System | Academic | 9 | 2014 to 2022 |
Showing 5 of 308 organizations.
Where GNAS appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
523 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.